WCLC 2025 - Posters & ePosters-P2.08 .48 Pacific Real-World Experience at Hospital Doce De Octubre

Pdf Summary

This study from Hospital Universitario 12 de Octubre in Madrid evaluates the real-world effectiveness and toxicity of chemoradiotherapy (CRT) followed by durvalumab in patients with unresectable stage III non-small cell lung cancer (NSCLC), reflecting findings from the pivotal PACIFIC trial. The cohort included 24 patients, with 67% receiving concurrent CRT (cCRT) and 33% sequential CRT (sCRT), followed by a median of 7.5 durvalumab cycles. The treatment demonstrated an objective response rate (ORR) of 54.2%, median overall survival (OS) of 31.3 months, and median progression-free survival (PFS) of 29.3 months. Five-year OS and PFS rates were 45% and 29%, respectively. Notably, patients undergoing cCRT experienced significantly better PFS compared to those receiving sCRT, though no difference in OS was found. Toxicity analysis revealed pneumonitis in 25% of patients, with two-thirds having severe (grade 3) cases, but no correlation between lung dosimetry metrics (mean lung dose ~20 Gy, V20 ~35%) and pneumonitis was identified. The study confirms that CRT followed by durvalumab improves outcomes consistent with PACIFIC trial results and highlights the higher efficacy of concurrent CRT over sequential CRT. However, given the frequency and severity of pneumonitis observed, close monitoring is essential. Overall, the findings support cCRT as the preferred treatment strategy when feasible, reinforcing its role as the standard of care in unresectable stage III NSCLC.

Asset Subtitle

Mariana Temes

Meta Tag

Speaker Mariana Temes

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

Hospital Universitario 12 de Octubre

Madrid

chemoradiotherapy

durvalumab

unresectable stage III non-small cell lung cancer

PACIFIC trial

concurrent chemoradiotherapy

sequential chemoradiotherapy

overall survival

pneumonitis